GLUD1 and colorectal carcinoma: In summary, our findings revealed that SIRT5 is a regulator of cancer glutaminolysis via its activation of GLUD1 in a deglutarylation-dependent manner, suggesting SIRT5 as a promising anti-CRC target for the selective killing of cancer cells.